
IPPOSI
IPPOSI
Funder
6 Projects, page 1 of 2
assignment_turned_in Project2008 - 2011Partners:INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, ERASMUS MC, AAU, Governo Italiano, deCODE Genetics (Iceland) +53 partnersINSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE,ERASMUS MC,AAU,Governo Italiano,deCODE Genetics (Iceland),VITRO S.A.,ISCIII,University of Turku,LSGi,GENOMA ESPAÑA,University of Manchester,MMI,ACC,GENERAL SECRETARIAT FOR RESEARCH AND INNOVATION,MUG,INCA,University of Salamanca,MPG,Helmholtz Zentrum München,MERIEUX ALLIANCE SA,ZON,IPPOSI,THL,HRB,Academy of Athens,Uppsala University,MRC,BMBF,UMCG,USMI,HARIDUS-JA TEADUS MINISTEERIUM,UK Biobank,LUMC,KI,LEGAL PATHWAYS BV,BBT,Telethon Foundation,University of Malta,USMI,FHF,MINISTERIE VAN ONDERWIJS, CULTUUR EN WETENSCHAP,IARC,BIOMEDICAL RESEARCH FOUNDATION, ACADEMY OF ATHENS,WHO,BUNDESMINISTERIUM FUR WISSENSCHAFT UND FORSCHUNG BMWF,iPRI,RANNIS,NTNU,HGFHELMHOLTZ ASSOCIATION OF GERMAN RESEARCH CENTRE,EMBL,NIPH,Semmelweis University,Cardiff University,CNR,UT,NEDERLANDSE FEDERATIE VAN UNIVERSITAIR MEDISCH CENTRA,Presidenza Del Consiglio Dei Ministri,FHGFunder: European Commission Project Code: 212111more_vert Open Access Mandate for Publications and Research data assignment_turned_in Project2025 - 2030Partners:IPPOSI, UCB, MHRA, TRIAL NATION, THE SYNERGIST +50 partnersIPPOSI,UCB,MHRA,TRIAL NATION,THE SYNERGIST,BMS,INFORMATION TECHNOLOGY FOR TRANSLATIONAL MEDICINE (ITTM) SA,FISABIO,Novo Nordisk,EDEX,AUH,Eli Lilly (United States),CHIESI,STICHTING EUPATI FOUNDATION,AbbVie,GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD.,SARD,PFIZER INC,TAK,NATIONAL CANCER INSTITUTE,AMGEN,ESPERITY,CENTRAL DENMARK EU OFFICE CDEU,UMC,SERGAS,Zabala Innovation Consulting (Spain),BIF,FONDAZIONE PENTA-FOR THE TREATMENT AND CARE OF CHILDREN WITH HIV-ONLUS,EUROPEAN PATIENTS FORUM,PAGALBOS ONKOLOGINIAMS LIGONIAMS ASOCIACIJA,ECRIN,AU,VU,CDISC,JDRF,HL7 INTERNATIONAL,SYNERGIST SERVICES,Almirall (Spain),KLINIKUM DER UNIVERSITAET ZU KOELN,FSJD-CERCA,FUNDATIA YOUTH CANCER EUROPE,FOUNDATION 29,SHINE 2EUROPE LDA,EUC,Curewiki,VICOM,AstraZeneca (Sweden),EATG,JANSSEN CILAG LIMITED,SYNAPSE RESEARCH MANAGEMENT PARTNERS SL,DiCE,GLOBAL HEART HUB COMPANY LIMITED BY GUARANTEE,NOVARTIS,Social IT,Roche (Switzerland)Funder: European Commission Project Code: 101166227Overall Budget: 66,860,900 EURFunder Contribution: 31,538,000 EURThe public-private partnership, READI, seeks to help clinical studies (CS) to finally serve the complete general population, and therefore more patients. To date CS have struggled to recruit and retain participants from diverse backgrounds and communities, such as marginalized or disadvantaged groups (e.g., sexual, gender, age, cultural, and socioeconomic cohorts). The resulting knowledge gaps entrench or increase health disparities. The READI consortium strives to tackle these challenges by fostering a more cohesive and integrated CS ecosystem for underserved (US) and underrepresented (UR) communities. It will actively connect all key stakeholders who can facilitate access to a wide range of patient populations. It will provide these stakeholders with the necessary tools, training programs, and approaches essential for the recruitment and retention of US/UR patients in CS. In addition, it will design, build and implement a digital platform which is patient-centred, sustainable, open and innovative. This will foster improved access to CS information and READI tools, while also supporting patient connections with the created communities. Finally, at least 4 CS will be used for testing the effectiveness of the developed tools and approaches. READI has a three-fold objective: to help US/UR communities overcome CS participation barriers (e.g., lack of information/awareness, mistrust, poor communication, geographic limitations, prejudice), which in turn will improve research of many diseases and conditions, preventative care and treatment effectiveness in different demographic groups, and better serve society. READI’s success will draw from its interdisciplinary, multi-stakeholder, consortium composition of 73 organizations from 18 countries, with key expertise in drug development and CS (design and operations), engagement strategies for US/UR populations, digital platform development, training and capability building initiatives, effective communication and dissemination, long-term sustainability, ethics and regulatory affairs.
more_vert Open Access Mandate for Publications and Research data assignment_turned_in Project2018 - 2020Partners:AbbVie, Bayer AG, Novo Nordisk, EUROPEAN PATIENTS FORUM, EATG +8 partnersAbbVie,Bayer AG,Novo Nordisk,EUROPEAN PATIENTS FORUM,EATG,EUROPEAN PATIENTS FORUM (EPF),EFGCP,IPPOSI,UCB,GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD.,NOVARTIS,UCPH,PFIZERFunder: European Commission Project Code: 806995Overall Budget: 604,042 EURFunder Contribution: 365,242 EURThe European Patients' Academy on Therapeutic Innovation (EUPATI) IMI project resulted in a number of key outputs for the field of patient engagement. The core activities continue running until 2019 under a PPP consortium under an EPF programme focusing on the Patient Expert Training Course, the multilingual public Toolbox, and the EUPATI National Platforms Network. It is imperative that these pillars that support the patient engagement landscape exist in the medium- and long-term to address the growing field of patient engagement. Further investment is needed to develop sustainable models of collaboration to ensure this, and put into place the infrastructure required for these to work, building on those already established under IMI-EUPATI.
more_vert Open Access Mandate for Publications and Research data assignment_turned_in Project2020 - 2022Partners:OYKS, SCMA, BEACON HOSPITAL, UCD, Aristotle University of Thessaloniki +5 partnersOYKS,SCMA,BEACON HOSPITAL,UCD,Aristotle University of Thessaloniki,ULP ,IPPOSI,ADHERA HEALTH SLU,EASP,NUIMFunder: European Commission Project Code: 873105Overall Budget: 998,279 EURFunder Contribution: 998,279 EURTen years from now, jobs will be more knowledge and skills-intensive than ever before. Globalisation and technological advances indicate that there will be changes in sectoral structure and demand for new types of skills we are not even currently anticipating. Currently only 30% of all doctoral graduates currently stay in academia with the remaining 70% seeking employment outside the academic setting, for example in industry and government . It is therefore clear that these graduates possess many of the required skills for purposeful employment outside academia. A gap has been identified in that current doctoral curricula do not foster big thinkers and creative problem-solvers, graduate attributes that society needs. There is a growing need to re-imagine a PhD education that incentivises doctoral students to engage with research consumers, not only within their discipline, but also, across other disciplines and sectors to have real social impact for an improved society. At a professional and research level, international, interdisciplinary and inter-sectoral networks are on the increase. Such collaborative doctoral programs can assist the knowledge society in finding innovative ways of approaching the world’s problems by asking creative questions and finding creative solutions within multiple employment contexts. To date, there is a lack of research in the area of the interdisciplinary, inter-sectoral doctoral education and the question remains: how do we best design these programmes to ensure that the PhD students’ develop into big thinkers? The overall aim of CHAMELONS is to develop a range of interdisciplinary, inter-sectoral and international modules which are designed to broaden the skills of PhD graduates and improve their employability in academic and non-academic environments.
more_vert assignment_turned_in Project2012 - 2017Partners:Janssen (Belgium), INFARMA, University of Manchester, BII GMBH, DIA +29 partnersJanssen (Belgium),INFARMA,University of Manchester,BII GMBH,DIA,UCPH,Roche (Switzerland),Johnson & Johnson (United States),Amgen,EAGS,IPPOSI,UCB,EATG,EFGCP,Farmaindustria,NOVARTIS,Novo Nordisk,MSD,ISPOR,PFIZER,Bayer Pharma AG,AstraZeneca (Sweden),ESTEVE,HIB,EORTC,Sanofi,EURORDIS - EUROPEAN ORGANISATION FOR RARE DISEASES ASSOCIATION,CHIESI,MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN,EUROPEAN PATIENTS FORUM (EPF),Eli Lilly and Company Limited,GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD.,BMS,VFAFunder: European Commission Project Code: 115334more_vert
chevron_left - 1
- 2
chevron_right